Profil
Michel Janicot worked as a Senior Director in Oncology Scientific Licensing at Johnson & Johnson and as a Senior Director in Research & Development at Janssen, Inc. Prior to that, he was the Head of Preclinical Research & Development at Isarna Therapeutics GmbH.
He also worked as a Principal at Rhone-Poulenc Rorer Pharmaceuticals, Inc. Dr. Janicot earned a doctorate degree from Université Paris Diderot-Paris 7 in 1988.
Anciens postes connus de Michel Janicot
| Sociétés | Poste | Fin |
|---|---|---|
Janssen, Inc.
 Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | Directeur Technique/Scientifique/R&D | - |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
| Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
Isarna Therapeutics GmbH
 Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Directeur Technique/Scientifique/R&D | - |
Formation de Michel Janicot
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| Entreprise privées | 4 |
|---|---|
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Health Technology |
| Rhone-Poulenc Rorer Pharmaceuticals, Inc. | |
| Université Paris Diderot-Paris 7 | Consumer Services |
Janssen, Inc.
Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | Health Technology |